AR024441A1 - Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento. - Google Patents

Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento.

Info

Publication number
AR024441A1
AR024441A1 ARP000103123A ARP000103123A AR024441A1 AR 024441 A1 AR024441 A1 AR 024441A1 AR P000103123 A ARP000103123 A AR P000103123A AR P000103123 A ARP000103123 A AR P000103123A AR 024441 A1 AR024441 A1 AR 024441A1
Authority
AR
Argentina
Prior art keywords
pirazol
prepare
pharmaceutical compositions
receptor agonists
medicinal product
Prior art date
Application number
ARP000103123A
Other languages
English (en)
Spanish (es)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR024441A1 publication Critical patent/AR024441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000103123A 1999-06-22 2000-06-22 Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento. AR024441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/338,185 US6403567B1 (en) 1999-06-22 1999-06-22 N-pyrazole A2A adenosine receptor agonists

Publications (1)

Publication Number Publication Date
AR024441A1 true AR024441A1 (es) 2002-10-02

Family

ID=23323763

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103123A AR024441A1 (es) 1999-06-22 2000-06-22 Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento.

Country Status (27)

Country Link
US (9) US6403567B1 (OSRAM)
EP (1) EP1189916B1 (OSRAM)
JP (1) JP4727880B2 (OSRAM)
KR (1) KR100463300B1 (OSRAM)
CN (1) CN1167709C (OSRAM)
AR (1) AR024441A1 (OSRAM)
AT (1) ATE256141T1 (OSRAM)
AU (1) AU760806B2 (OSRAM)
BE (1) BE2011C004I2 (OSRAM)
BR (1) BRPI0011856B8 (OSRAM)
CA (1) CA2377746C (OSRAM)
CY (1) CY2011002I1 (OSRAM)
DE (2) DE122011000010I1 (OSRAM)
DK (1) DK1189916T3 (OSRAM)
ES (1) ES2209974T3 (OSRAM)
FR (1) FR11C0004I2 (OSRAM)
HK (1) HK1044952B (OSRAM)
IL (2) IL147198A0 (OSRAM)
LU (1) LU91785I2 (OSRAM)
MX (1) MXPA01013325A (OSRAM)
NO (2) NO322457B1 (OSRAM)
NZ (1) NZ516334A (OSRAM)
PT (1) PT1189916E (OSRAM)
TR (1) TR200200588T2 (OSRAM)
TW (1) TWI230161B (OSRAM)
WO (1) WO2000078779A2 (OSRAM)
ZA (1) ZA200200301B (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) * 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001062979A2 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
HUP0402591A2 (hu) 2002-02-15 2005-09-28 Cv Therapeutics, Inc. Polimer bevonat orvosi eszközök számára
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
AU2003268526A1 (en) 2002-09-09 2004-03-29 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
JP4818127B2 (ja) * 2004-01-27 2011-11-16 ギリアード・パロ・アルト・インコーポレイテッド アデノシン受容体作動薬を使用する心筋灌流イメージング方法
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
BRPI0510406A (pt) * 2004-05-26 2007-12-26 Inotek Pharmaceuticals Corp derivados de purina como agonistas do receptor de adenosina a1 e métodos de uso destes
ATE531377T1 (de) * 2004-09-20 2011-11-15 Inotek Pharmaceuticals Corp Purin-derivate und anwendungsverfahren
CA2583185A1 (en) * 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7732424B2 (en) * 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
CA2640089C (en) * 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ATE549337T1 (de) * 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DE102006020349A1 (de) 2006-04-28 2007-10-31 Mahle International Gmbh Kolbenmotor und zugehöriges Betriebsverfahren
US7691825B2 (en) * 2006-06-06 2010-04-06 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor agonists
JP2009541354A (ja) * 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP2056834B1 (en) * 2006-09-01 2012-08-29 Gilead Sciences, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20100041918A1 (en) * 2006-11-10 2010-02-18 Novartis Ag Cyclopentene diol monoacetate derivatives
CA2673653A1 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
CN101668768B (zh) * 2007-05-17 2012-08-29 吉利德帕洛阿尔托股份有限公司 制备a2a-腺苷受体激动剂及其多晶型物的方法
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US7899039B2 (en) * 2008-02-15 2011-03-01 Cisco Technology, Inc. System and method for providing location and access network information support in a network environment
PL2300489T3 (pl) * 2008-06-06 2016-11-30 Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych
US20100086483A1 (en) * 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy
US7957314B2 (en) * 2008-12-12 2011-06-07 Cisco Technology, Inc. System and method for provisioning charging and policy control in a network environment
WO2011085361A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
WO2011119969A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US9215588B2 (en) 2010-04-30 2015-12-15 Cisco Technology, Inc. System and method for providing selective bearer security in a network environment
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
WO2012149196A1 (en) 2011-04-27 2012-11-01 Reliable Biopharmaceutical Corporation Improved processes for the preparation of regadenoson and a new crystalline form thereof
CZ308577B6 (cs) 2011-08-18 2020-12-16 Farmak, A. S. Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu
CZ304053B6 (cs) 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
EA027109B1 (ru) 2012-01-26 2017-06-30 Инотек Фармасьютикалс Корпорейшн Безводные полиморфы [(2r,3s,4r,5r)-5-(6-(циклопентиламино)-9h-пурин-9-ил)-3,4-дигидрокситетрагидрофуран-2-ил]метилнитрата и способы их получения
US20150290236A1 (en) * 2012-11-30 2015-10-15 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
KR20150139501A (ko) 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
ES2837751T3 (es) 2013-04-11 2021-07-01 Amri Italy S R L Formas sólidas estables de regadenoson
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
WO2014207758A2 (en) 2013-05-30 2014-12-31 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of regadenoson
CN104513241B (zh) * 2013-09-30 2017-02-08 浙江海正药业股份有限公司 瑞加德松新中间体及其制备方法和应用
CN104744540A (zh) * 2013-12-26 2015-07-01 上海紫源制药有限公司 一种制备瑞加德松的方法
CN105085593A (zh) * 2014-04-21 2015-11-25 上海紫源制药有限公司 瑞加德松的晶型及其制备方法
US10442832B2 (en) 2015-02-06 2019-10-15 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
US9809617B2 (en) 2015-07-03 2017-11-07 Shanghai Ziyuan Pharmaceutical Co., Ltd. Crystal form of regadenoson and preparation method thereof
CN106397442B (zh) * 2015-07-28 2020-03-27 国药集团国瑞药业有限公司 一种瑞加德松的纯化方法
JP7100854B2 (ja) 2017-01-13 2022-07-14 東菱薬品工業株式会社 好中球活性化調節剤
WO2019191389A1 (en) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Solid-state forms of regadenoson, their use and preparation
US10815265B2 (en) 2018-06-29 2020-10-27 Usv Private Limited Process for preparation of regadenoson and polymorphs thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4990498A (en) * 1988-04-26 1991-02-05 Temple University-Of The Commonwealth System Of Higher Education 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
DE68916036T2 (de) 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
US5283327A (en) 1989-06-20 1994-02-01 Yamasa Shoyu Kabushiki Kaisha Tri-O-acetyl-2-alkynyladenosines
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
WO1993025677A1 (en) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
EP0601322A3 (en) 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5477857A (en) 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5703085A (en) * 1994-02-23 1997-12-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
JP2002505687A (ja) 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU4675699A (en) 1998-06-08 1999-12-30 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
DE60001969T2 (de) 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
WO2002092556A1 (en) 2001-05-14 2002-11-21 Novartis Ag Sulfonamide derivatives
IL161867A0 (en) * 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EA007468B1 (ru) * 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003235466C1 (en) 2002-04-18 2008-03-20 Gilead Palo Alto, Inc. Method for treating arrhythmias
WO2004011010A1 (en) 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JP4818127B2 (ja) 2004-01-27 2011-11-16 ギリアード・パロ・アルト・インコーポレイテッド アデノシン受容体作動薬を使用する心筋灌流イメージング方法
US20060159627A1 (en) * 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
EP1841355A4 (en) 2005-01-12 2012-09-05 King Pharmaceuticals Res & Dev METHOD FOR DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS SUFFERING IN THE ASTHMA OR BRONCHOSPASM PASS
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
JP2009541354A (ja) 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP2056834B1 (en) 2006-09-01 2012-08-29 Gilead Sciences, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (ja) 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
CA2673653A1 (en) 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
CN101668768B (zh) 2007-05-17 2012-08-29 吉利德帕洛阿尔托股份有限公司 制备a2a-腺苷受体激动剂及其多晶型物的方法
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
US20100086483A1 (en) * 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy

Also Published As

Publication number Publication date
US20070203090A1 (en) 2007-08-30
BR0011856A (pt) 2004-02-10
WO2000078779A3 (en) 2001-03-15
US7144872B2 (en) 2006-12-05
NO20016350D0 (no) 2001-12-21
JP2003506461A (ja) 2003-02-18
FR11C0004I1 (fr) 2011-03-11
AU760806B2 (en) 2003-05-22
US20060052332A1 (en) 2006-03-09
CA2377746A1 (en) 2000-12-28
IL147198A0 (en) 2002-08-14
CY2011002I2 (el) 2012-01-25
BE2011C004I2 (OSRAM) 2019-05-21
KR100463300B1 (ko) 2004-12-23
NO322457B1 (no) 2006-10-09
NZ516334A (en) 2004-05-28
HK1044952A1 (en) 2002-11-08
NO2011002I1 (no) 2011-03-07
US8569260B2 (en) 2013-10-29
CN1167709C (zh) 2004-09-22
EP1189916A2 (en) 2002-03-27
US7655637B2 (en) 2010-02-02
ES2209974T3 (es) 2004-07-01
ZA200200301B (en) 2003-11-26
BR0011856B1 (pt) 2014-06-17
DE60007127T2 (de) 2004-09-16
US6403567B1 (en) 2002-06-11
US20110144320A1 (en) 2011-06-16
DE60007127D1 (de) 2004-01-22
US20130058866A1 (en) 2013-03-07
TWI230161B (en) 2005-04-01
NO2011002I2 (no) 2012-10-22
EP1189916B1 (en) 2003-12-10
NO20016350L (no) 2002-02-18
US8278435B2 (en) 2012-10-02
US9045519B2 (en) 2015-06-02
US20040038928A1 (en) 2004-02-26
US20100160620A1 (en) 2010-06-24
MXPA01013325A (es) 2002-07-02
KR20020028910A (ko) 2002-04-17
FR11C0004I2 (fr) 2012-03-16
HK1044952B (zh) 2005-02-25
CY2011002I1 (el) 2012-01-25
IL147198A (en) 2006-04-10
CA2377746C (en) 2007-04-10
PT1189916E (pt) 2004-03-31
AU7132400A (en) 2001-01-09
JP4727880B2 (ja) 2011-07-20
CN1358191A (zh) 2002-07-10
WO2000078779A2 (en) 2000-12-28
TR200200588T2 (tr) 2002-09-23
DE122011000010I1 (de) 2011-06-16
US6642210B1 (en) 2003-11-04
DK1189916T3 (da) 2004-03-22
BRPI0011856B8 (pt) 2021-05-25
ATE256141T1 (de) 2003-12-15
US20140073596A1 (en) 2014-03-13
US7183264B2 (en) 2007-02-27
LU91785I2 (fr) 2011-03-31

Similar Documents

Publication Publication Date Title
AR024441A1 (es) Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento.
AR024440A1 (es) AGONISTAS DEL RECEPTOR A2A DE ETER PROPARGIL FENILICO, COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO.
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR024345A1 (es) Derivados de purina
AR026052A1 (es) Derivados de purina
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
UY26332A1 (es) Nuevos derivados del ácido aminodicarboxílico con propiedades farmacéuticas.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
AR035348A1 (es) Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos
ES2084944T3 (es) Amidas terapeuticas.
ECSP003712A (es) Derivados de la purina
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
AR009741A1 (es) Nuevos derivados de la benzamidina, procedimiento para prepararlos, preparados farmaceuticos que los contienen y su empleo como medicamentos.
PL378238A1 (pl) Związki biaromatyczne, które aktywują receptory typu PPAR<$Egamma>, oraz ich zastosowanie w kompozycjach kosmetycznych albo farmaceutycznych
MX9300616A (es) Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.

Legal Events

Date Code Title Description
FG Grant, registration